Phase 3 trial of adcetris® (brentuximab vedotin) with modified chemo regimen shows non-inferiority with unprecedented 3-year progression free survival of 94.9% vs less tolerable international standard of care in advanced classical hodgkin lymphoma

Bothell, wash.--(business wire)-- #hl--seagen inc. (nasdaq: sgen) today announced that the clinical research cooperative german hodgkin study group (ghsg) presented results showing that a phase 3 trial of adcetris® in combination with chemotherapy – a regimen called brecadd (brentuximab vedotin [adcetris], etoposide, cyclophosphamide, doxorubicin [adriamycin], dacarbazine, and dexamethasone) – met its co-primary endpoints of non-inferior efficacy and superior tolerability versus a highly efficacious.
SGEN Ratings Summary
SGEN Quant Ranking